UK Disregards EPO’s Opinion On Everolimus Patent
An EPO opposition finding that a patent is invalid has not stopped a UK court from issuing an injunction against Dr Reddy’s generic everolimus on the grounds that the same patent is infringed.
You may also be interested in...
Novartis' everolimus oncology brand, Afinitor, and AstraZeneca's dapagliflozin-based Farxiga diabetes treatment are the focus of January's review of expiring intellectual-property rights, based on IQVIA's Ark Patent Intelligence Database.
A US Court of Appeals issues a precedential opinion concerning patent terms affected by a change in law by Congress in the mid-90s, in a ruling on Novartis’ everolimus compound patent shielding the originator’s Afinitor and Zortress brands.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.